The Balearic squad and the club agreed a few days ago a salary reduction of 15% in the event that the competition does not return and in this sense Xisco affirms that the decision “has not been very difficult, with two talks with the Board of Directors an agreement was reached, from the beginning it is a matter of logic, the competition stops and obviously measures have to be taken , the club situation is explained to us a bit and also our concern is also the people of the club who do not have our income and we were willing to collaborate“ The captain of Real Mallorca, Xisco Campos, has held since his confinement a press conference with the island’s media to review various aspects of current affairs, Among those who have highlighted the possible return of the competition, the qualifying situation and the drop in salaries of the staff. On the stage that is presented to be able to return to the competition gradually and progressively, the Mallorcan central defender points out that “in my opinion the most feasible scenario to end the season is to advance the individual training sessions, which would be phase 1, and then make a good protocol in which all parties see what can be done once we have the security of health, of the authorities, of the League, players, physical trainers, sports doctors and everyone, and at that point we will have to sit down and make the right decisionOne day we have to start, but we have to do it at the right time. “Regarding the plan to return to the competition, Xisco assures that “the club has informed us and we are evaluating it, we know it is made by specialists, for health, and the soccer players together with the workers have to see what can be done that is safe and with health ahead “. In this sense, Xisco adds that” we are at the expense of the administrations, the authorities, so they give us permission to train starting with phase 1 and then see how we are doing it with a lot of measures that we have to take because, apart from wanting to play again, we are talking about a health issue that is a priority. “Sportingly, and with the team in a relegation position, the Majorcan player does not contemplate a relegation because “it would be unfair”, adding that “I think it would not be good for us to be descended when the competition is not really over and the options to save are more than possiblebut these are not things that depend on us. “
Source:http://en.misis.ru/university/news/science/2018-08/5504/ Aug 17 2018The new treatment will serve as both diagnosis and treatment of malignant tumors. This breakthrough in the technologies of cancer diagnosis and treatment was made by an interdisciplinary Russian-German collaboration of chemists, physicists, and biologists from NUST MISIS, Lomonosov Moscow State University, Pirogov Russian National Research Medical University (RNRMU), and the University of Duisburg-Essen (Germany).For the first time ever, scientists have shown that a hybrid nanomaterial based on magnetite-gold particles can serve as a universal platform to both detect cancer cells anywhere in the body and to complete targeted deliveries of drugs to these cells. The discovery makes it possible to create and implement a completely new generation of cancer treatments in the coming years.The results of this fundamental research conducted at the intersection of physics, chemistry, biology and medicine have been published in Scientific Reports, one of the most prestigious scientific journals.”The interdisciplinary collaboration of scientists led by Maxim Abakumov, a Candidate of Chemical Sciences and the Head of the NUST MISIS Biomedical Nanomaterials Laboratory, has managed to develop a platform for simultaneous diagnosis and treatment of cancer. The aggregation of diagnosis and therapy at the cellular level — so-called theranostics — is now considered one of the most promising areas in modern medicine. Scientists now [have] to learn how to detect pathogenic cells at the earliest stage of the disease”, said Alevtina Chernikova, Rector of NUST MISIS.If these pathogenic cells are tagged with magnetic nanoparticles, they can be diagnosed with the help of magnetic resonance imaging (MRI) and subsequently destroyed by either a drug or a magnetic field that heats and kills cancer cells.”We have managed to combine gold (Au) and magnetite (Fe3O4) nanoparticles into a hybrid that has both magnetic properties and is capable of carrying the drug [to a tumor]. It turned out as a kind of ‘nanodumbbell’ which could become a platform — a universal base — of future theranostics, and we have shown that in our research”, said Maxim Abakumov, one of the project participants, assistant professor at RNRMU, and Head of the NUST MISIS Biomedical Nanomaterials Laboratory.Related StoriesHow cell-free DNA can be targeted to prevent spread of tumorsLiving with advanced breast cancerSugary drinks linked to cancer finds studyThis manmade nanohybrid has been tested both in vitro and in vivo. Laboratory tests on mice with grafted tumors have already been completed.”The article considers a model of a mouse breast tumor and shows the possibility to deliver the hybrid Fe3O4-Au particles to the tumor, loaded with the anti-tumor drug doxorubicin. The drug is released inside the tumor and has a therapeutic influence”, added Mariya Efremova, the project`s co-worker, junior research assistant at the Laboratory for Chemical Design of Bionanomaterials for Medical Applications at Lomonosov Moscow State University, and an engineer at the NUST MISIS Biomedical Nanomaterials Laboratory.It is possible to place almost any drug (in place of doxorubicin) into the “nanodumbbell”, and this makes this hybrid an ideal platform to detect tumor cells and deliver drugs; previously proposed methods were only suitable for certain types of drugs and only worked on certain types of cancer cells. Such versatility allows us to hope for the emergence of a new generation of treatments for malignant tumors in the coming years.According to the most optimistic researchers on the project, it will be possible to proceed to pre-clinical trials in just two to three years time, as there is a few years’ of work remaining to be completed before clinical trials on real patients. However, the concept of theranostics has still not been applied in clinical practice anywhere in the world, although Russian scientists are on the front lines of this area.”As a scientific discipline, theranostics is now developing very quickly. The proposed platform demonstrates impressive and diverse effectiveness in lab conditions, however, it still has a long way [to go before getting] to patients”, said Marina Sekacheva, Head of the Center for Personalized Oncology “OncoTarget” at Sechenov University. Sekacheva believes that doctors should provide maximum practical support to fundamental scientists and continuously work with them on potentially groundbreaking projects such as this one.